Nucleoside diphosphate kinase 6 (NME6)

Nucleoside diphosphate kinase 6 (NME6) is a mitochondrial nucleoside diphosphate kinase enzyme that plays a critical role in the synthesis of nucleoside triphosphates other than ATP, particularly by supplying pyrimidine ribonucleotides (rNTPs) for mitochondrial transcription and supporting maintenance of mitochondrial DNA under conditions of limited cytosolic nucleotide import[1][2][3][4]. NME6 is predominantly localized in the mitochondrial matrix, associates with the inner mitochondrial membrane, and obtains its enzymatic activity through interaction with RCC1L, forming a unique kinase-active complex. In addition to fueling mitochondrial RNA synthesis and respiratory function, NME6 also acts as an inhibitor of p53-induced apoptosis. Genetic ablation of NME6 disrupts mitochondrial gene expression and function, contributing to various pathologies, including cancer, mitochondrial dysfunction, and impaired energy metabolism[1][2][3][4].

Other names

NM23-H6NDK 6IPIA-alphaInhibitor of p53-induced apoptosis-alphanon-metastatic cells 6NM23 nucleoside diphosphate kinase 6NDP kinase 6IPIA-ALPHA

Not established for therapeutic drugs as of September 2025; the enzyme catalyzes the transfer of gamma-phosphates between nucleoside diphosphates and triphosphates, fueling mitochondrial RNA transcription and DNA maintenance[1][2][3][4].